MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-02-2026
Twist Bioscience Corporation Operating Income 2011-2026 | TWST
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Twist Bioscience Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -136 M | -221 M | -217 M | -235 M | -153 M | -140 M | -109 M | -70.6 M | -58.5 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -58.5 M | -235 M | -149 M |
Quarterly Operating Income Twist Bioscience Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.9 M | - | -30.1 M | -41.6 M | -34.6 M | - | -88.9 M | -48.9 M | -47 M | - | -60.8 M | -61.6 M | -44.6 M | -178 M | -61.2 M | -60.8 M | -55.9 M | -113 M | -42.1 M | -38 M | -32.8 M | -116 M | -28.2 M | -32.8 M | -55.8 M | -77.3 M | -28.1 M | -55.8 M | -22.9 M | -50.9 M | -17.5 M | -22.9 M | -16.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -16.8 M | -178 M | -53.3 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 116.96 | 1.23 % | $ 35.6 B |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.72 | 2.99 % | $ 2.29 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.0 | 2.21 % | $ 694 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.37 | 0.66 % | $ 1.14 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 16.33 | 0.12 % | $ 494 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 128.0 | 0.09 % | $ 20.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 171.98 | 1.3 % | $ 8.52 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 88.84 | -0.08 % | $ 11.1 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 84.31 | -0.03 % | $ 5.69 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.98 | -2.37 % | $ 8.76 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 412.77 | 0.54 % | $ 11.9 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.63 | 0.58 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 7.05 | - | $ 294 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.6 | 0.58 % | $ 2.08 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.12 | -0.93 % | $ 4.87 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.33 | 0.55 % | $ 388 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 101.21 | -0.94 % | $ 8.35 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 263.81 | 0.03 % | $ 21.9 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 473.8 | 0.9 % | $ 179 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 125.71 | 3.87 % | $ 5.88 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.64 | -1.34 % | $ 61.9 M | Irlanda |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.41 | 1.45 % | $ 1.08 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.91 | 2.72 % | $ 455 M | USA |
 |
Natera
NTRA
|
-541 M | $ 206.02 | 1.11 % | $ 20.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 196.49 | 0.14 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
357 M | - | -0.91 % | $ 14.7 B | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |